Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T56365
(Former ID: TTDC00135)
|
|||||
| Target Name |
B-lymphocyte surface antigen B4 (CD19)
|
|||||
| Synonyms |
T-cell surface antigen Leu-12; Leu-12; Differentiation antigen CD19; B-lymphocyte antigen CD19
|
|||||
| Gene Name |
CD19
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Diffuse large B-cell lymphoma [ICD-11: 2A81] | |||||
| 2 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
| 3 | Nervous system paraneoplastic/autoimmune disorder [ICD-11: 8E4A] | |||||
| Function |
Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes.
Click to Show/Hide
|
|||||
| BioChemical Class |
Immunoglobulin
|
|||||
| UniProt ID | ||||||
| Sequence |
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKP
FLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGE LFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSL NQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMW VMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYL IFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSG LGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEF YENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLS PHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGP DPAWGGGGRMGTWSTR Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| HIT2.0 ID | T88WHQ | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 7 Approved Drugs | + | ||||
| 1 | Axicabtagene ciloleucel | Drug Info | Approved | Diffuse large B-cell lymphoma | [2] | |
| 2 | Blinatumomab | Drug Info | Approved | Acute lymphoblastic leukaemia | [3], [4] | |
| 3 | Inebilizumab | Drug Info | Approved | Neuromyelitis optica spectrum disorder | [5] | |
| 4 | Lisocabtagene maraleucel | Drug Info | Approved | Large B-cell lymphoma | [6] | |
| 5 | Loncastuximab tesirine | Drug Info | Approved | Diffuse large B-cell lymphoma | [7] | |
| 6 | Tecartus | Drug Info | Approved | Mantle cell lymphoma | [8] | |
| 7 | Tisagenlecleucel | Drug Info | Approved | Acute lymphoblastic leukaemia | [2] | |
| Clinical Trial Drug(s) | [+] 171 Clinical Trial Drugs | + | ||||
| 1 | CART-19 | Drug Info | Phase 2/3 | Acute lymphoblastic leukaemia | [9] | |
| 2 | CD19 CAR T cells | Drug Info | Phase 2/3 | Acute lymphoblastic leukaemia | [10] | |
| 3 | MOR-208 | Drug Info | Phase 2/3 | Diffuse large B-cell lymphoma | [11], [12], [13] | |
| 4 | CAR-T cells targeting CD19 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [14] | |
| 5 | CART 19 | Drug Info | Phase 2 | Acute lymphoblastic leukaemia | [15], [16] | |
| 6 | CART-19 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [17] | |
| 7 | CART-19 cells | Drug Info | Phase 2 | Multiple myeloma | [18] | |
| 8 | CD19 CAR T cells | Drug Info | Phase 2 | B-cell chronic lymphocytic leukaemia | [19] | |
| 9 | CD19-targeting CAR T cells | Drug Info | Phase 2 | B-cell lymphoma | [20], [21] | |
| 10 | Coltuximab ravtansine | Drug Info | Phase 2 | Diffuse large B-cell lymphoma | [12] | |
| 11 | CTL019 | Drug Info | Phase 2 | Diffuse large B-cell lymphoma | [22], [23] | |
| 12 | JCAR015 | Drug Info | Phase 2 | B-cell lymphoma | [24] | |
| 13 | KYMRIAH | Drug Info | Phase 2 | Acute lymphoblastic leukaemia | [25] | |
| 14 | MB-CART19.1 | Drug Info | Phase 2 | Precursor B-lymphoblastic neoplasm | [26] | |
| 15 | MDX-1342 | Drug Info | Phase 2 | leukaemia | [27] | |
| 16 | MEDI-551 | Drug Info | Phase 2 | Encephalopathy | [11] | |
| 17 | SAR-3419 | Drug Info | Phase 2 | Non-hodgkin lymphoma | [28] | |
| 18 | XLCART001 | Drug Info | Phase 2 | B-cell lymphoma | [29] | |
| 19 | Xmab 5871 | Drug Info | Phase 2 | Autoimmune diabetes | [30] | |
| 20 | 4SCAR19 and 4SCAR123 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 21 | 4SCAR19 and 4SCAR20 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 22 | 4SCAR19 and 4SCAR22 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 23 | 4SCAR19 and 4SCAR30 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 24 | 4SCAR19 and 4SCAR38 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 25 | 4SCAR19 and 4SCAR70 | Drug Info | Phase 1/2 | B-cell lymphoma | [31] | |
| 26 | 4SCAR19 cells | Drug Info | Phase 1/2 | B-cell lymphoma | [32] | |
| 27 | 4SCAR19/22 T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [33] | |
| 28 | Anti-CD19 and Anti-CD20 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [34] | |
| 29 | Anti-CD19 CAR T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [35], [36] | |
| 30 | Anti-CD19 CAR transduced T cells | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [37] | |
| 31 | Anti-CD19 CAR-T | Drug Info | Phase 1/2 | Haematopoietic/lymphoid cancer | [38] | |
| 32 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [39] | |
| 33 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [40] | |
| 34 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [41], [42] | |
| 35 | Anti-CD19 CAR-T cells | Drug Info | Phase 1/2 | B-cell chronic lymphocytic leukaemia | [43] | |
| 36 | Anti-CD19-CAR PBL | Drug Info | Phase 1/2 | Mantle cell lymphoma | [44] | |
| 37 | Anti-CD19-CAR vector-transduced T cells | Drug Info | Phase 1/2 | Mantle cell lymphoma | [45], [46] | |
| 38 | Anti-CD19-CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [47] | |
| 39 | Anti-CD19/22-CAR vector-transduced T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [48] | |
| 40 | Anti-CD20 CAR-T cells | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [49] | |
| 41 | AUTO1 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [50] | |
| 42 | AUTO3 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [51] | |
| 43 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [52] | |
| 44 | Autologous CD19-targeting CAR T cells | Drug Info | Phase 1/2 | leukaemia | [53] | |
| 45 | CAR-T cells targeting CD19 | Drug Info | Phase 1/2 | leukaemia | [54] | |
| 46 | CARCIK-CD19 | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [55] | |
| 47 | CART-19 cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [56] | |
| 48 | CART-19/22 | Drug Info | Phase 1/2 | leukaemia | [57] | |
| 49 | CART-19/BCMA | Drug Info | Phase 1/2 | Multiple myeloma | [58] | |
| 50 | CD19 and CD20 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [59] | |
| 51 | CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | Lymphoma | [60] | |
| 52 | CD19 and CD22 CAR-T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [59] | |
| 53 | CD19 CAR Gene Transduced T Lymphocytes | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [61] | |
| 54 | CD19 CAR T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [62] | |
| 55 | CD19 CAR T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [63] | |
| 56 | CD19 CAR-T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [64] | |
| 57 | CD19 CAR-T lymphocytes | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [65] | |
| 58 | CD19 CART | Drug Info | Phase 1/2 | B-cell lymphoma | [66] | |
| 59 | CD19 CART | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [67] | |
| 60 | CD19 specific CAR T cells | Drug Info | Phase 1/2 | Acute leukaemia | [68] | |
| 61 | CD19 targeted chimeric antigen receptor T cells | Drug Info | Phase 1/2 | B-cell lymphoma | [69] | |
| 62 | CD19-CAR T cell | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [70] | |
| 63 | CD19-directed CAR-T cells | Drug Info | Phase 1/2 | leukaemia | [71] | |
| 64 | CD19-targeting CAR T Cells | Drug Info | Phase 1/2 | B-cell lymphoma | [72] | |
| 65 | CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells | Drug Info | Phase 1/2 | Haematopoietic/lymphoid cancer | [73] | |
| 66 | CD19.CAR T Cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [74] | |
| 67 | CD19.CAR-T cells | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [75] | |
| 68 | Chimeric Antigen Receptor Modified T cells Targeting CD19 | Drug Info | Phase 1/2 | leukaemia | [76] | |
| 69 | CLIC-1901 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [77] | |
| 70 | Humanized CD19 CAR-T cells | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [78] | |
| 71 | IM19 CAR-T | Drug Info | Phase 1/2 | leukaemia | [79], [80] | |
| 72 | JCAR014 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [81] | |
| 73 | JCAR017 | Drug Info | Phase 1/2 | Chronic lymphocytic leukaemia | [82], [83] | |
| 74 | KTE-C19 CAR | Drug Info | Phase 1/2 | Diffuse large B-cell lymphoma | [84] | |
| 75 | PBCAR0191 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [85] | |
| 76 | PCAR-019 | Drug Info | Phase 1/2 | Acute lymphocytic leukaemia | [86] | |
| 77 | SCRI-huCAR19v1 | Drug Info | Phase 1/2 | leukaemia | [87] | |
| 78 | SJCAR19 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [88] | |
| 79 | TAK-007 | Drug Info | Phase 1/2 | Hematologic tumour | [89] | |
| 80 | TBI-1501 | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [90] | |
| 81 | TC-110 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [91] | |
| 82 | TriCAR-T-CD19 | Drug Info | Phase 1/2 | Non-hodgkin lymphoma | [92] | |
| 83 | UCART019 | Drug Info | Phase 1/2 | B-cell lymphoma | [93] | |
| 84 | 19-28z T CELLS | Drug Info | Phase 1 | Non-hodgkin lymphoma | [94] | |
| 85 | 4SCAR19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [95] | |
| 86 | AFM11 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [96], [12] | |
| 87 | ALLO-501 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [97] | |
| 88 | Allogeneic CART-19 | Drug Info | Phase 1 | leukaemia | [98] | |
| 89 | AMG 562 | Drug Info | Phase 1 | Diffuse large B-cell lymphoma | [99] | |
| 90 | Anti-CD19 anti-CD20 Bispecific CAR-T | Drug Info | Phase 1 | leukaemia | [100] | |
| 91 | Anti-CD19 CAR-T | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [101] | |
| 92 | Anti-CD19 CAR-T cells | Drug Info | Phase 1 | leukaemia | [102] | |
| 93 | Anti-CD19 CART Cells | Drug Info | Phase 1 | Multiple myeloma | [103] | |
| 94 | Anti-CD19 EBV CTL therapy | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [104] | |
| 95 | Anti-CD19-CAR | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [105] | |
| 96 | Anti-CD19-CAR T | Drug Info | Phase 1 | leukaemia | [106] | |
| 97 | Anti-CD19-CAR T cells | Drug Info | Phase 1 | B-cell lymphoma | [107] | |
| 98 | Anti-CD19/BCMA CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [108] | |
| 99 | AntiCD19 CART | Drug Info | Phase 1 | Non-hodgkin lymphoma | [109] | |
| 100 | ARI-0001 cells | Drug Info | Phase 1 | leukaemia | [110] | |
| 101 | BCMA CART and huCART19 | Drug Info | Phase 1 | Multiple myeloma | [111] | |
| 102 | BCMA-CD19 cCAR | Drug Info | Phase 1 | Multiple myeloma | [112] | |
| 103 | C-CAR011 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [113], [114] | |
| 104 | CAR-20/19-T Cells | Drug Info | Phase 1 | B-cell non-hodgkin lymphoma | [115] | |
| 105 | CAR-T cells targeting CD19 | Drug Info | Phase 1 | Lymphoma | [116] | |
| 106 | CAR-T Cells targeting CD19 | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [117] | |
| 107 | CAR19 T cells carrying cytoplasmic activated PD-1 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [118] | |
| 108 | CART-19 | Drug Info | Phase 1 | B-cell lymphoma | [119] | |
| 109 | CART-19 | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [120] | |
| 110 | CART-19 autologous T-cells | Drug Info | Phase 1 | Lymphoma | [121] | |
| 111 | CART-19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [122] | |
| 112 | CART-19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [123] | |
| 113 | CART-19 T cells | Drug Info | Phase 1 | Multiple myeloma | [124] | |
| 114 | CART-meso-19 T cells | Drug Info | Phase 1 | Pancreatic cancer | [125] | |
| 115 | CART19 cell | Drug Info | Phase 1 | B-cell prolymphocytic leukaemia | [126] | |
| 116 | CART22-65s cells and huCART19 Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [127] | |
| 117 | CARTmeso/19 | Drug Info | Phase 1 | Pancreatic cancer | [128] | |
| 118 | CarVAC | Drug Info | Phase 1 | B-cell lymphoma | [129] | |
| 119 | CC-97540 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [130] | |
| 120 | CD19 CAR T | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [131] | |
| 121 | CD19 CAR T Cells | Drug Info | Phase 1 | Acute lymphocytic leukaemia | [132] | |
| 122 | CD19 CAR T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [133] | |
| 123 | CD19 CAR T-cells | Drug Info | Phase 1 | Non-hodgkin lymphoma | [134] | |
| 124 | CD19 CAR T-cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [135] | |
| 125 | CD19 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [136] | |
| 126 | CD19 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [137] | |
| 127 | CD19 Redirected Autologous T Cells | Drug Info | Phase 1 | Systemic lupus erythematosus | [138] | |
| 128 | CD19+ CAR T Cells | Drug Info | Phase 1 | leukaemia | [139] | |
| 129 | CD19-CAR and CD28-CAR T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [140] | |
| 130 | CD19-CAR-T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [141] | |
| 131 | CD19-CAR-T2 Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [142] | |
| 132 | CD19-directed CAR-T cells | Drug Info | Phase 1 | Non-hodgkin lymphoma | [143] | |
| 133 | CD19-directed CAR-T cells | Drug Info | Phase 1 | leukaemia | [144] | |
| 134 | CD19-targeted CART cells | Drug Info | Phase 1 | leukaemia | [145] | |
| 135 | CD19-TriCAR-T | Drug Info | Phase 1 | Non-hodgkin lymphoma | [146] | |
| 136 | CD19.CAR-aNKT cells | Drug Info | Phase 1 | B-cell small lymphocytic lymphoma | [147] | |
| 137 | CD19/CD22 CAR T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [148] | |
| 138 | CD19/CD22 CAR T-Cells | Drug Info | Phase 1 | Acute lymphocytic leukaemia | [149] | |
| 139 | CD19/CD22 Chimeric Antigen Receptor T Cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [150] | |
| 140 | CD19CAT-41BBZ CAR T-cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [151] | |
| 141 | CD19t-haNK | Drug Info | Phase 1 | Diffuse large B-cell lymphoma | [152] | |
| 142 | CD20-CD19 cCAR | Drug Info | Phase 1 | B-cell lymphoma | [153] | |
| 143 | Combotox | Drug Info | Phase 1 | leukaemia | [154] | |
| 144 | CTX-101 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [155] | |
| 145 | Donor-derived CD19/22 bispecific CAR-T cells | Drug Info | Phase 1 | leukaemia | [144] | |
| 146 | Duvortuxizumab | Drug Info | Phase 1 | B-cell lymphoma | [13] | |
| 147 | EGFRt/19-28z/4-1BBL CAR T cells | Drug Info | Phase 1 | Chronic lymphocytic leukaemia | [156] | |
| 148 | FT-819 | Drug Info | Phase 1 | Chronic lymphocytic leukaemia | [157] | |
| 149 | HuCART19 | Drug Info | Phase 1 | leukaemia | [158] | |
| 150 | Human CD19 targeted T Cells | Drug Info | Phase 1 | Follicular lymphoma | [159] | |
| 151 | IC9-CAR19 cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [160], [161] | |
| 152 | IC9-CAR19 T cells | Drug Info | Phase 1 | B-cell lymphoma | [162] | |
| 153 | ICAR19 CAR-T cells | Drug Info | Phase 1 | B-cell lymphoma | [163] | |
| 154 | IM19 | Drug Info | Phase 1 | Haematological malignancy | [164] | |
| 155 | JWCAR029 | Drug Info | Phase 1 | Non-hodgkin lymphoma | [165] | |
| 156 | KUR-502 | Drug Info | Phase 1 | B-cell lymphoma | [166] | |
| 157 | MEDl-551 | Drug Info | Phase 1 | Scleroderma | [167] | |
| 158 | Patient-derived CD19- and CD22 specific CAR | Drug Info | Phase 1 | leukaemia | [168] | |
| 159 | PZ01 CAR-T cells | Drug Info | Phase 1 | Acute lymphoblastic leukaemia | [169] | |
| 160 | Sleeping Beauty CAR-TCR | Drug Info | Phase 1 | leukaemia | [170] | |
| 161 | TG-1801 | Drug Info | Phase 1 | B-cell lymphoma | [171] | |
| 162 | TNB-486 | Drug Info | Phase 1 | B-cell lymphoma | [172] | |
| 163 | YTB323 | Drug Info | Phase 1 | Diffuse large B-cell lymphoma | [173] | |
| 164 | Anti-CD19 Chimeric Antigen Receptor T Cells | Drug Info | Clinical trial | leukaemia | [174] | |
| 165 | Anti-CD19/20-CAR vector-transduced T cells | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [175] | |
| 166 | CAR-CD19 T cell | Drug Info | Clinical trial | B-cell lymphoma | [176] | |
| 167 | CD19-CAR T Cells | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [177] | |
| 168 | CD19-targeted CAR-T cells | Drug Info | Clinical trial | leukaemia | [178] | |
| 169 | CD19-targeted CAR-T cells | Drug Info | Clinical trial | leukaemia | [179] | |
| 170 | CD19-UCART | Drug Info | Clinical trial | Acute lymphoblastic leukaemia | [180] | |
| 171 | CD19CART | Drug Info | Clinical trial | B-cell lymphoma | [181] | |
| Preclinical Drug(s) | [+] 5 Preclinical Drugs | + | ||||
| 1 | Anti-CD19 CAR T cells | Drug Info | Phase 0 | Hodgkin lymphoma | [182] | |
| 2 | CART19 cells | Drug Info | Phase 0 | Hodgkin lymphoma | [183] | |
| 3 | ATA2431 | Drug Info | Preclinical | B-cell lymphoma | [184] | |
| 4 | ATA3219 | Drug Info | Preclinical | B-cell lymphoma | [184] | |
| 5 | SGN-19A | Drug Info | Preclinical | Haematological malignancy | [185] | |
| Mode of Action | [+] 5 Modes of Action | + | ||||
| CAR-T-Cell-Therapy | [+] 115 CAR-T-Cell-Therapy drugs | + | ||||
| 1 | Axicabtagene ciloleucel | Drug Info | [186] | |||
| 2 | Lisocabtagene maraleucel | Drug Info | [6] | |||
| 3 | CART-19 | Drug Info | [9] | |||
| 4 | CD19 CAR T cells | Drug Info | [10], [188] | |||
| 5 | CAR-T cells targeting CD19 | Drug Info | [14] | |||
| 6 | CART 19 | Drug Info | [15], [16], [190] | |||
| 7 | CART-19 | Drug Info | [17], [191], [192], [193], [194] | |||
| 8 | CART-19 cells | Drug Info | [195], [18] | |||
| 9 | CD19 CAR T cells | Drug Info | [19] | |||
| 10 | CD19-targeting CAR T cells | Drug Info | [20], [21] | |||
| 11 | CTL019 | Drug Info | [22], [23] | |||
| 12 | JCAR015 | Drug Info | [24] | |||
| 13 | KYMRIAH | Drug Info | [25] | |||
| 14 | MB-CART19.1 | Drug Info | [26] | |||
| 15 | XLCART001 | Drug Info | [29] | |||
| 16 | 4SCAR19 cells | Drug Info | [32] | |||
| 17 | Anti-CD19 CAR T cells | Drug Info | [35], [36] | |||
| 18 | Anti-CD19 CAR transduced T cells | Drug Info | [37] | |||
| 19 | Anti-CD19 CAR-T | Drug Info | [38] | |||
| 20 | Anti-CD19 CAR-T cells | Drug Info | [39] | |||
| 21 | Anti-CD19 CAR-T cells | Drug Info | [40] | |||
| 22 | Anti-CD19 CAR-T cells | Drug Info | [41], [42] | |||
| 23 | Anti-CD19 CAR-T cells | Drug Info | [43] | |||
| 24 | Anti-CD19-CAR PBL | Drug Info | [44] | |||
| 25 | Anti-CD19-CAR vector-transduced T cells | Drug Info | [45], [46] | |||
| 26 | Anti-CD19-CAR-T cells | Drug Info | [47] | |||
| 27 | Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Drug Info | [52] | |||
| 28 | Autologous CD19-targeting CAR T cells | Drug Info | [53] | |||
| 29 | CAR-T cells targeting CD19 | Drug Info | [54] | |||
| 30 | CARCIK-CD19 | Drug Info | [55] | |||
| 31 | CART-19 cells | Drug Info | [56] | |||
| 32 | CD19 CAR Gene Transduced T Lymphocytes | Drug Info | [61] | |||
| 33 | CD19 CAR T Cells | Drug Info | [62] | |||
| 34 | CD19 CAR T cells | Drug Info | [63] | |||
| 35 | CD19 CAR-T Cells | Drug Info | [64] | |||
| 36 | CD19 CAR-T lymphocytes | Drug Info | [65] | |||
| 37 | CD19 CART | Drug Info | [66] | |||
| 38 | CD19 CART | Drug Info | [67] | |||
| 39 | CD19 specific CAR T cells | Drug Info | [68] | |||
| 40 | CD19 targeted chimeric antigen receptor T cells | Drug Info | [69] | |||
| 41 | CD19-CAR T cell | Drug Info | [70] | |||
| 42 | CD19-directed CAR-T cells | Drug Info | [71] | |||
| 43 | CD19-targeting CAR T Cells | Drug Info | [72] | |||
| 44 | CD19.CAR T Cells | Drug Info | [74] | |||
| 45 | CD19.CAR-T cells | Drug Info | [75] | |||
| 46 | Chimeric Antigen Receptor Modified T cells Targeting CD19 | Drug Info | [76] | |||
| 47 | CLIC-1901 | Drug Info | [77] | |||
| 48 | Humanized CD19 CAR-T cells | Drug Info | [78] | |||
| 49 | IM19 CAR-T | Drug Info | [79], [80] | |||
| 50 | JCAR014 | Drug Info | [202] | |||
| 51 | JCAR017 | Drug Info | [82], [203], [83] | |||
| 52 | PBCAR0191 | Drug Info | [85] | |||
| 53 | PCAR-019 | Drug Info | [86] | |||
| 54 | SCRI-huCAR19v1 | Drug Info | [87] | |||
| 55 | SJCAR19 | Drug Info | [88] | |||
| 56 | TBI-1501 | Drug Info | [90] | |||
| 57 | TriCAR-T-CD19 | Drug Info | [92] | |||
| 58 | UCART019 | Drug Info | [93] | |||
| 59 | 19-28z T CELLS | Drug Info | [94] | |||
| 60 | 4SCAR19 cells | Drug Info | [95] | |||
| 61 | Allogeneic CART-19 | Drug Info | [98] | |||
| 62 | Anti-CD19 CAR-T | Drug Info | [101] | |||
| 63 | Anti-CD19 CAR-T cells | Drug Info | [102] | |||
| 64 | Anti-CD19 CART Cells | Drug Info | [103] | |||
| 65 | Anti-CD19-CAR | Drug Info | [105] | |||
| 66 | Anti-CD19-CAR T | Drug Info | [106] | |||
| 67 | Anti-CD19-CAR T cells | Drug Info | [107] | |||
| 68 | AntiCD19 CART | Drug Info | [109] | |||
| 69 | ARI-0001 cells | Drug Info | [110] | |||
| 70 | C-CAR011 | Drug Info | [113], [114] | |||
| 71 | CAR-T cells targeting CD19 | Drug Info | [116] | |||
| 72 | CAR-T Cells targeting CD19 | Drug Info | [117] | |||
| 73 | CAR19 T cells carrying cytoplasmic activated PD-1 | Drug Info | [118] | |||
| 74 | CART-19 | Drug Info | [119] | |||
| 75 | CART-19 | Drug Info | [120] | |||
| 76 | CART-19 autologous T-cells | Drug Info | [121] | |||
| 77 | CART-19 cells | Drug Info | [122] | |||
| 78 | CART-19 cells | Drug Info | [123] | |||
| 79 | CART-19 T cells | Drug Info | [124] | |||
| 80 | CART19 cell | Drug Info | [126] | |||
| 81 | CD19 CAR T | Drug Info | [131] | |||
| 82 | CD19 CAR T Cells | Drug Info | [132] | |||
| 83 | CD19 CAR T cells | Drug Info | [133], [211] | |||
| 84 | CD19 CAR T-cells | Drug Info | [134] | |||
| 85 | CD19 CAR T-cells | Drug Info | [135] | |||
| 86 | CD19 CAR-T cells | Drug Info | [136] | |||
| 87 | CD19 CAR-T cells | Drug Info | [137] | |||
| 88 | CD19 Redirected Autologous T Cells | Drug Info | [138] | |||
| 89 | CD19+ CAR T Cells | Drug Info | [139] | |||
| 90 | CD19-CAR-T Cells | Drug Info | [141] | |||
| 91 | CD19-CAR-T2 Cells | Drug Info | [142] | |||
| 92 | CD19-directed CAR-T cells | Drug Info | [143] | |||
| 93 | CD19-directed CAR-T cells | Drug Info | [144] | |||
| 94 | CD19-targeted CART cells | Drug Info | [145] | |||
| 95 | CD19-TriCAR-T | Drug Info | [146] | |||
| 96 | CD19.CAR-aNKT cells | Drug Info | [147] | |||
| 97 | CD19CAT-41BBZ CAR T-cells | Drug Info | [151] | |||
| 98 | EGFRt/19-28z/4-1BBL CAR T cells | Drug Info | [156] | |||
| 99 | HuCART19 | Drug Info | [158] | |||
| 100 | Human CD19 targeted T Cells | Drug Info | [159] | |||
| 101 | IC9-CAR19 cells | Drug Info | [160], [161] | |||
| 102 | IC9-CAR19 T cells | Drug Info | [162] | |||
| 103 | ICAR19 CAR-T cells | Drug Info | [163] | |||
| 104 | IM19 | Drug Info | [216], [164] | |||
| 105 | JWCAR029 | Drug Info | [165] | |||
| 106 | PZ01 CAR-T cells | Drug Info | [169] | |||
| 107 | Anti-CD19 Chimeric Antigen Receptor T Cells | Drug Info | [174] | |||
| 108 | CAR-CD19 T cell | Drug Info | [176] | |||
| 109 | CD19-CAR T Cells | Drug Info | [177] | |||
| 110 | CD19-targeted CAR-T cells | Drug Info | [220], [221], [178] | |||
| 111 | CD19-targeted CAR-T cells | Drug Info | [179] | |||
| 112 | CD19-UCART | Drug Info | [180] | |||
| 113 | CD19CART | Drug Info | [181] | |||
| 114 | Anti-CD19 CAR T cells | Drug Info | [182] | |||
| 115 | CART19 cells | Drug Info | [183] | |||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | Blinatumomab | Drug Info | [1] | |||
| 2 | Xmab 5871 | Drug Info | [198], [199] | |||
| 3 | Combotox | Drug Info | [213] | |||
| 4 | Anti-CD22/CD19 mab-toxin conjugate | Drug Info | [222] | |||
| Inhibitor | [+] 6 Inhibitor drugs | + | ||||
| 1 | Inebilizumab | Drug Info | [5] | |||
| 2 | Loncastuximab tesirine | Drug Info | [187] | |||
| 3 | Coltuximab ravtansine | Drug Info | [13] | |||
| 4 | KTE-C19 CAR | Drug Info | [204] | |||
| 5 | AFM11 | Drug Info | [206] | |||
| 6 | AMG 562 | Drug Info | [207] | |||
| Immunostimulant | [+] 1 Immunostimulant drugs | + | ||||
| 1 | Tisagenlecleucel | Drug Info | [2] | |||
| CAR-T-Cell-Therapy(Dual specific) | [+] 31 CAR-T-Cell-Therapy(Dual specific) drugs | + | ||||
| 1 | 4SCAR19 and 4SCAR123 | Drug Info | [31] | |||
| 2 | 4SCAR19 and 4SCAR20 | Drug Info | [31] | |||
| 3 | 4SCAR19 and 4SCAR22 | Drug Info | [31] | |||
| 4 | 4SCAR19 and 4SCAR30 | Drug Info | [31] | |||
| 5 | 4SCAR19 and 4SCAR38 | Drug Info | [31] | |||
| 6 | 4SCAR19 and 4SCAR70 | Drug Info | [31] | |||
| 7 | 4SCAR19/22 T cells | Drug Info | [33] | |||
| 8 | Anti-CD19 and Anti-CD20 CAR-T Cells | Drug Info | [34] | |||
| 9 | Anti-CD19/22-CAR vector-transduced T cells | Drug Info | [48] | |||
| 10 | Anti-CD20 CAR-T cells | Drug Info | [49] | |||
| 11 | AUTO3 | Drug Info | [51], [201] | |||
| 12 | CART-19/22 | Drug Info | [57] | |||
| 13 | CART-19/BCMA | Drug Info | [58] | |||
| 14 | CD19 and CD20 CAR-T Cells | Drug Info | [59] | |||
| 15 | CD19 and CD22 CAR-T Cells | Drug Info | [60] | |||
| 16 | CD19 and CD22 CAR-T Cells | Drug Info | [59] | |||
| 17 | CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells | Drug Info | [73] | |||
| 18 | Anti-CD19 anti-CD20 Bispecific CAR-T | Drug Info | [100] | |||
| 19 | Anti-CD19/BCMA CAR-T cells | Drug Info | [108] | |||
| 20 | BCMA CART and huCART19 | Drug Info | [111] | |||
| 21 | CAR-20/19-T Cells | Drug Info | [115] | |||
| 22 | CART-meso-19 T cells | Drug Info | [125] | |||
| 23 | CART22-65s cells and huCART19 Cells | Drug Info | [127] | |||
| 24 | CARTmeso/19 | Drug Info | [128] | |||
| 25 | CD19-CAR and CD28-CAR T Cells | Drug Info | [140] | |||
| 26 | CD19/CD22 CAR T cells | Drug Info | [148] | |||
| 27 | CD19/CD22 CAR T-Cells | Drug Info | [149] | |||
| 28 | CD19/CD22 Chimeric Antigen Receptor T Cells | Drug Info | [150] | |||
| 29 | Donor-derived CD19/22 bispecific CAR-T cells | Drug Info | [144] | |||
| 30 | Patient-derived CD19- and CD22 specific CAR | Drug Info | [168] | |||
| 31 | Anti-CD19/20-CAR vector-transduced T cells | Drug Info | [175] | |||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-regulating Transcription Factors | ||||||
| Target-interacting Proteins | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 5 KEGG Pathways | + | ||||
| 1 | PI3K-Akt signaling pathway | |||||
| 2 | Hematopoietic cell lineage | |||||
| 3 | B cell receptor signaling pathway | |||||
| 4 | Epstein-Barr virus infection | |||||
| 5 | Primary immunodeficiency | |||||
| NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
| 1 | IL-7 Signaling Pathway | |||||
| Panther Pathway | [+] 1 Panther Pathways | + | ||||
| 1 | B cell activation | |||||
| PID Pathway | [+] 1 PID Pathways | + | ||||
| 1 | BCR signaling pathway | |||||
| Reactome | [+] 4 Reactome Pathways | + | ||||
| 1 | PIP3 activates AKT signaling | |||||
| 2 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
| 3 | Constitutive Signaling by Aberrant PI3K in Cancer | |||||
| 4 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| WikiPathways | [+] 5 WikiPathways | + | ||||
| 1 | Human Complement System | |||||
| 2 | Signaling by the B Cell Receptor (BCR) | |||||
| 3 | PIP3 activates AKT signaling | |||||
| 4 | B Cell Receptor Signaling Pathway | |||||
| 5 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||||
| REF 2 | 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. | |||||
| REF 3 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | |||||
| REF 4 | ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | |||||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||||
| REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. | |||||
| REF 7 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||||
| REF 8 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. | |||||
| REF 9 | ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL | |||||
| REF 10 | ClinicalTrials.gov (NCT03391739) CART-19 Cells For R/R B-ALL | |||||
| REF 11 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 12 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 13 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 14 | ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL | |||||
| REF 15 | ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | |||||
| REF 16 | ClinicalTrials.gov (NCT02906371) Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | |||||
| REF 17 | ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | |||||
| REF 18 | ClinicalTrials.gov (NCT02794246) CART-19 Post-ASCT for Multiple Myeloma | |||||
| REF 19 | ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | |||||
| REF 20 | ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | |||||
| REF 21 | ClinicalTrials.gov (NCT03068416) CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy | |||||
| REF 22 | ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. | |||||
| REF 23 | ClinicalTrials.gov (NCT03601442) CTL019 Out of Specification MAP for ALL or DLBCL Patients | |||||
| REF 24 | ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL). | |||||
| REF 25 | ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies | |||||
| REF 26 | ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL | |||||
| REF 27 | ClinicalTrials.gov (NCT01974479) Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia. U.S. National Institutes of Health. | |||||
| REF 28 | A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. | |||||
| REF 29 | ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | |||||
| REF 30 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125) | |||||
| REF 31 | ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies | |||||
| REF 32 | ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies | |||||
| REF 33 | ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | |||||
| REF 34 | ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma | |||||
| REF 35 | ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma | |||||
| REF 36 | ClinicalTrials.gov (NCT02247609) Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas | |||||
| REF 37 | ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | |||||
| REF 38 | ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | |||||
| REF 39 | ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | |||||
| REF 40 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | |||||
| REF 41 | ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | |||||
| REF 42 | ClinicalTrials.gov (NCT03366350) Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | |||||
| REF 43 | ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy | |||||
| REF 44 | ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | |||||
| REF 45 | ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma | |||||
| REF 46 | ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | |||||
| REF 47 | ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia | |||||
| REF 48 | ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | |||||
| REF 49 | ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | |||||
| REF 50 | ClinicalTrials.gov (NCT04404660) A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL). U.S. National Institutes of Health. | |||||
| REF 51 | ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL | |||||
| REF 52 | ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | |||||
| REF 53 | ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy | |||||
| REF 54 | ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | |||||
| REF 55 | ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT | |||||
| REF 56 | ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL | |||||
| REF 57 | ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | |||||
| REF 58 | ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | |||||
| REF 59 | ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | |||||
| REF 60 | ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | |||||
| REF 61 | ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes | |||||
| REF 62 | ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | |||||
| REF 63 | ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | |||||
| REF 64 | ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | |||||
| REF 65 | ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | |||||
| REF 66 | ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | |||||
| REF 67 | ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL | |||||
| REF 68 | ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | |||||
| REF 69 | ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | |||||
| REF 70 | ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL | |||||
| REF 71 | ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy | |||||
| REF 72 | ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma | |||||
| REF 73 | ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy | |||||
| REF 74 | ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | |||||
| REF 75 | ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma | |||||
| REF 76 | ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | |||||
| REF 77 | ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | |||||
| REF 78 | ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia | |||||
| REF 79 | ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells | |||||
| REF 80 | ClinicalTrials.gov (NCT03173417) Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) | |||||
| REF 81 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075) | |||||
| REF 82 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | |||||
| REF 83 | ClinicalTrials.gov (NCT03331198) Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | |||||
| REF 84 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039436) | |||||
| REF 85 | ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL | |||||
| REF 86 | ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | |||||
| REF 87 | ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma | |||||
| REF 88 | ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | |||||
| REF 89 | Clinical pipeline report, company report or official report of Takeda. | |||||
| REF 90 | ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | |||||
| REF 91 | ClinicalTrials.gov (NCT04323657) TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia. U.S. National Institutes of Health. | |||||
| REF 92 | ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 | |||||
| REF 93 | ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | |||||
| REF 94 | ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | |||||
| REF 95 | ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | |||||
| REF 96 | ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health. | |||||
| REF 97 | Clinical pipeline report, company report or official report of Allogene Therapeutics. | |||||
| REF 98 | ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | |||||
| REF 99 | ClinicalTrials.gov (NCT03571828) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma. U.S. National Institutes of Health. | |||||
| REF 100 | ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | |||||
| REF 101 | ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | |||||
| REF 102 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | |||||
| REF 103 | ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | |||||
| REF 104 | ClinicalTrials.gov (NCT00840853) Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT). U.S. National Institutes of Health. | |||||
| REF 105 | ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | |||||
| REF 106 | ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | |||||
| REF 107 | ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies | |||||
| REF 108 | ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | |||||
| REF 109 | ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | |||||
| REF 110 | ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy | |||||
| REF 111 | ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | |||||
| REF 112 | ClinicalTrials.gov (NCT04162353) BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma. U.S. National Institutes of Health. | |||||
| REF 113 | ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL | |||||
| REF 114 | ClinicalTrials.gov (NCT03154775) Study of Safety and Efficacy of C-CAR011 in B-NHL Patients | |||||
| REF 115 | ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells | |||||
| REF 116 | ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma | |||||
| REF 117 | ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | |||||
| REF 118 | ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma | |||||
| REF 119 | ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | |||||
| REF 120 | ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | |||||
| REF 121 | ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP | |||||
| REF 122 | ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | |||||
| REF 123 | ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | |||||
| REF 124 | ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma | |||||
| REF 125 | ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer | |||||
| REF 126 | ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | |||||
| REF 127 | ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL | |||||
| REF 128 | ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer | |||||
| REF 129 | ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health. | |||||
| REF 130 | ClinicalTrials.gov (NCT04231747 ) A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | |||||
| REF 131 | ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies | |||||
| REF 132 | ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | |||||
| REF 133 | ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | |||||
| REF 134 | ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | |||||
| REF 135 | ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies | |||||
| REF 136 | ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | |||||
| REF 137 | ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | |||||
| REF 138 | ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) | |||||
| REF 139 | ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies | |||||
| REF 140 | ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia | |||||
| REF 141 | ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL | |||||
| REF 142 | ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | |||||
| REF 143 | ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects | |||||
| REF 144 | ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | |||||
| REF 145 | ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | |||||
| REF 146 | ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy | |||||
| REF 147 | ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | |||||
| REF 148 | ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia | |||||
| REF 149 | ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | |||||
| REF 150 | ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia | |||||
| REF 151 | ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19 | |||||
| REF 152 | ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health. | |||||
| REF 153 | ClinicalTrials.gov (NCT04156178) CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies. U.S. National Institutes of Health. | |||||
| REF 154 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027936) | |||||
| REF 155 | ClinicalTrials.gov (NCT04035434) A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). U.S. National Institutes of Health. | |||||
| REF 156 | ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | |||||
| REF 157 | ClinicalTrials.gov (NCT04629729) FT819 in Subjects With B-cell Malignancies. U.S. National Institutes of Health. | |||||
| REF 158 | ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy | |||||
| REF 159 | ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | |||||
| REF 160 | ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia | |||||
| REF 161 | ClinicalTrials.gov (NCT03594162) Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | |||||
| REF 162 | ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | |||||
| REF 163 | ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | |||||
| REF 164 | ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells | |||||
| REF 165 | ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | |||||
| REF 166 | Clinical pipeline report, company report or official report of Kuur Therapeutics. | |||||
| REF 167 | CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. | |||||
| REF 168 | ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma | |||||
| REF 169 | ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma | |||||
| REF 170 | Clinical pipeline report, company report or official report of Ziopharm Oncology. | |||||
| REF 171 | ClinicalTrials.gov (NCT03804996) Study of TG-1801 in Subjects With B-Cell Lymphoma. U.S. National Institutes of Health. | |||||
| REF 172 | ClinicalTrials.gov (NCT04594642) A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health. | |||||
| REF 173 | ClinicalTrials.gov (NCT03960840) CD19-specific CAR-T Cells in CLL/SLL and DLBCL. U.S. National Institutes of Health. | |||||
| REF 174 | ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies | |||||
| REF 175 | ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | |||||
| REF 176 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | |||||
| REF 177 | ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation | |||||
| REF 178 | ClinicalTrials.gov (NCT02735291) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia | |||||
| REF 179 | ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation | |||||
| REF 180 | ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART | |||||
| REF 181 | ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | |||||
| REF 182 | ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma | |||||
| REF 183 | ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | |||||
| REF 184 | Clinical pipeline report, company report or official report of Atara Biotherapeutics. | |||||
| REF 185 | 2011 Pipeline of Seattle Genetics. | |||||
| REF 186 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services | |||||
| REF 187 | Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645. | |||||
| REF 188 | ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma | |||||
| REF 189 | A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. | |||||
| REF 190 | ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | |||||
| REF 191 | ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | |||||
| REF 192 | ClinicalTrials.gov (NCT01747486) CD19 Redirected Autologous T Cells | |||||
| REF 193 | ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | |||||
| REF 194 | ClinicalTrials.gov (NCT02030847) Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia | |||||
| REF 195 | ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol | |||||
| REF 196 | A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. | |||||
| REF 197 | Clinical pipeline report, company report or official report of MedImmune (2011). | |||||
| REF 198 | Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64. | |||||
| REF 199 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. | |||||
| REF 200 | Clinical pipeline report, company report or official report of Autolus Therapeutics. | |||||
| REF 201 | ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | |||||
| REF 202 | ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | |||||
| REF 203 | ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | |||||
| REF 204 | Clinical pipeline report, company report or official report of Kite Pharma. | |||||
| REF 205 | Clinical pipeline report, company report or official report of TCR2 Therapeutics. | |||||
| REF 206 | A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604. | |||||
| REF 207 | Clinical pipeline report, company report or official report of Amgen. | |||||
| REF 208 | Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia. 2010 May;24(5):1080-4. | |||||
| REF 209 | Clinical pipeline report, company report or official report of iCell Gene Therapeutics. | |||||
| REF 210 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | |||||
| REF 211 | ClinicalTrials.gov (NCT03029338) CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma | |||||
| REF 212 | Clinical pipeline report, company report or official report of iCell Gene Therapeutics. | |||||
| REF 213 | A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. | |||||
| REF 214 | Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. | |||||
| REF 215 | Clinical pipeline report, company report or official report of Fate Therapeutics. | |||||
| REF 216 | ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | |||||
| REF 217 | Clinical pipeline report, company report or official report of TG Theraputics. | |||||
| REF 218 | Clinical pipeline report, company report or official report of Teneobio. | |||||
| REF 219 | Clinical pipeline report, company report or official report of Novartis. | |||||
| REF 220 | ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma | |||||
| REF 221 | ClinicalTrials.gov (NCT03488160) CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma | |||||
| REF 222 | Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.